Efficacy and Safety Outcomes from the MATISSE Phase 3 Trial of Maternal Bivalent RSVpreF Vaccination Among Pregnant Women Vaccinated at 32 to 36 Weeks of Gestation. Swiss Med Wkly 2026, 156 (1), 4711. https://doi.org/10.57187/4711.